Foon K A, Sherwin S A, Abrams P G, Longo D L, Fer M F, Stevenson H C, Ochs J J, Bottino G C, Schoenberger C S, Zeffren J
N Engl J Med. 1984 Nov 1;311(18):1148-52. doi: 10.1056/NEJM198411013111803.
We report the results of a trial of recombinant leukocyte A interferon in previously treated patients with non-Hodgkin's lymphoma who were no longer responsive to chemotherapy. Patients received recombinant leukocyte A interferon (50 X 10(6) U per square meter of body-surface area) by intramuscular injection three times weekly for three months or longer. Forty-five patients were enrolled in the study, and 37 were evaluated for a response. Thirteen of 24 (54 per cent) evaluable patients with low-histologic-grade non-Hodgkin's lymphoma had objective responses (nine partial responses and four histologically confirmed complete responses). Two of six (33 per cent) with intermediate-grade lymphoma responded (one partially and one completely), and one of seven (14 per cent) with high-grade lymphoma had a partial response. The median duration of responses was eight months. Four of the five complete responders have continued to receive maintenance interferon and have been in complete remission for 3, 7, 9, and 12 months, respectively; one had a recurrence at a site of previous disease seven months after interferon had been stopped. Side effects were noted in most patients. All 16 responders had been heavily pretreated with combination chemotherapy, including doxorubicin in 8 of the 16. These results suggest that recombinant leukocyte A interferon may be an effective new therapy for some patients with low- and intermediate-grade non-Hodgkin's lymphoma.
我们报告了一项针对既往接受过治疗但对化疗不再有反应的非霍奇金淋巴瘤患者进行的重组白细胞A干扰素试验结果。患者通过肌肉注射接受重组白细胞A干扰素（每平方米体表面积50×10⁶单位），每周三次，持续三个月或更长时间。45名患者参与了该研究，37名患者接受了疗效评估。在24名可评估的低组织学分级非霍奇金淋巴瘤患者中，13名（54%）有客观反应（9名部分缓解，4名经组织学证实为完全缓解）。6名中级淋巴瘤患者中有2名（33%）有反应（1名部分缓解，1名完全缓解），7名高级淋巴瘤患者中有1名（14%）有部分缓解。反应的中位持续时间为8个月。5名完全缓解者中有4名继续接受维持性干扰素治疗，分别已完全缓解3、7、9和12个月；1名在停用干扰素7个月后，原发病灶处复发。大多数患者出现了副作用。所有16名有反应者都曾接受过包括阿霉素在内的联合化疗的强烈预处理，16名中有8名使用过阿霉素。这些结果表明，重组白细胞A干扰素可能是一些低级别和中级非霍奇金淋巴瘤患者的一种有效的新疗法。
